Browse the evidence

Semaglutide treatment following catheter ablation for atrial fibrillation is associated with a lower rate of atrial arrhythmia recurrence over 12 months (hazard ratio, 0.68; P =0.030).

Practitioners may consider semaglutide as a therapeutic option to reduce atrial arrhythmia recurrence post-ablation.

In men, a 14.4% ILI-associated increase in total testosterone at year 1 mediated increases in weight (189 g; 95% CI, 65-317) and waist circumference (0.135 cm; 95% CI, 0.19-0.248) at year 4.

Practitioners should consider the role of testosterone in managing weight and waist circumference in men with type 2 diabetes.

In women, a 21.8% decrease in bioavailable testosterone at year 1 mediated decreases in whole-body fat mass (-164; 95% CI, -326 to -29.3), whole-body lean mass (-115 g; 95% CI, -203.4 to -40), and trunk lean mass (-97.2 g; 95% CI, -156 to -45.5) at year 4.

Practitioners should consider the role of bioavailable testosterone in managing body composition in women with type 2 diabetes.

The study revealed sex-specific mediating effects of sex hormones due to weight loss from intensive lifestyle intervention on body composition changes in people with type 2 diabetes.

Practitioners should tailor weight loss recommendations based on sex differences in hormone responses.

49% of patients receiving semaglutide treatment had a full stomach compared to 18% of matched controls.

Clinicians should be aware of the increased risk of full stomach in patients on semaglutide during pre-operative assessments.

Semaglutide improved hemoglobin A1c levels and reduced glycemic variability without increasing hypoglycemia.

Semaglutide may enhance glycemic control in type 1 diabetes patients.

Tirzepatide has potential cardiovascular benefits.

Practitioners should consider the cardiovascular implications when prescribing TZP.

Significant improvements were observed across quality-of-life scores.

Incorporating exercise and nutrition can enhance the quality of life for breast cancer patients.

Incretin mimetics have a positive impact on related comorbidities, such as sleep apnea and heart failure.

Practitioners should be aware of the broader health benefits of incretin mimetics beyond glucose control.

Patients may benefit from education on proper drug administration, anticipated adverse effects, and nutrition considerations with treatment.

Educating patients on these aspects can improve treatment adherence and outcomes.

GLP-1 RA therapy improved HBA1C levels from 6.4 to 5.7 (p-value 0.003) in LVAD patients.

GLP-1 RA may help improve glycemic control in LVAD patients.

Dulaglutide showed consistent reductions in HbA1c (1.1%) and weight (1.2 kg).

Dulaglutide is an effective alternative for glycemic control and weight management in T2DM patients.

Several emerging oral agents have demonstrated promising efficacy, achieving weight loss of ≥10% in clinical trials.

Practitioners may consider these oral agents as effective options for weight management.

Incretin-based therapy reduced all-cause mortality by 18%.

Incretin-based therapies may improve survival rates in overweight or obese individuals.

The total daily dose (TDD) of insulin decreased from 183 ± 98 units to 143 ± 99 units over 6 months (P < 0.001).

Clinicians may consider semaglutide as a viable option to reduce insulin requirements in T2DM patients.

Obesity leads to inflammation and altered hormone production that can promote cancer development.

Understanding the hormonal and inflammatory changes in obesity can help in developing targeted interventions for cancer prevention.

Semaglutide was associated with a reduction in heavy drinking days by -41.1 percentage points from baseline compared to placebo, which had a reduction of -26.4 percentage points.

Semaglutide may be a viable treatment option for reducing heavy drinking in patients with alcohol use disorder and obesity.

Semaglutide improved heart failure symptoms and physical limitations in participants with obesity-related HFpEF.

Practitioners can consider semaglutide as an effective treatment for improving symptoms in patients with obesity-related HFpEF.

Semaglutide treatment shows significant interactions based on sex at both 1.7 mg and 2.4 mg doses compared to placebo.

Clinicians should consider sex as a factor when prescribing semaglutide for weight loss.

Semaglutide 2.4 mg shows significant treatment interactions based on the presence of type 2 diabetes and dyslipidemia at baseline compared to placebo.

Healthcare providers should assess comorbidities when evaluating the potential effectiveness of semaglutide.

HEC-C046, with high GCG receptor selectivity, shows significant weight loss and improvement in MASLD parameters but raises safety concerns.

Practitioners should consider the balance between efficacy and safety when using dual receptor agonists.

HEC-C052, with the lowest GCG agonism, is less effective for weight loss compared to semaglutide.

Semaglutide may be preferred over HEC-C052 for weight loss in certain populations.

Randomized trials with liraglutide and semaglutide have shown reductions in major adverse cardiovascular events.

These medications may be beneficial for patients at high risk of cardiovascular events.

Tirzepatide was recently approved for the management of obesity.

Tirzepatide can be considered as a treatment option for obesity management.